About Us
A&G was incorporated in Delaware as a “C” Corporation on June 6, 2000. A&G has raised over $14 million in capital to date and is looking to finish clinical trials and FDA submission for 2 diagnostic kits for breast cancer.
Besides our own theranostic product development, A&G has a unique proprietary antibody technology that can develop mouse monoclonal antibodies in as little as 30 days with a success rate over 90%. We use this platform to generate antibodies for researchers at academic, government, and biotech/pharmaceutical organizations. The industry average for developing monoclonal antibodies is 180 days with a 25% success rate. With the ability to generate antibodies 2 to 4 times faster than our competition, A&G has quickly become recognized by organizations such as NIH as one of the fastest and best mouse monoclonal antibody developers in the world. Over the last four years, A&G has become the preferred partner for more than 14 biotech and pharmaceutical organizations in monoclonal antibody development.
We are very excited about the future opportunities at A&G and believe, with good reason, that it’s an excellent time - not only to take a closer look at A&G Pharmaceutical - but also to participate in our future.